The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase I-II study to evaluate safety and efficacy of niraparib plus cabozantinib in patients with advanced urothelial/kidney cancer (NICARAGUA trial): Preliminary data of phase I study.
 
Daniel E. Castellano
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Ipsen; Janssen Oncology; Lilly; MSD Oncology; Novartis; Pfizer; Pierre Fabre; Roche/Genentech; Sanofi; Sanofi
Research Funding - Janssen Oncology (Inst)
Travel, Accommodations, Expenses - AstraZeneca Spain; Bristol-Myers Squibb; Pfizer; Roche
 
Ignacio Duran
Honoraria - Astellas Pharma; Bristol-Myers Squibb; EUSA Pharma; Ipsen; Janssen Oncology; MSD Oncology; Roche/Genentech
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Immunomedics; Janssen Oncology; MSD Oncology; Novartis; Pharmacyclics; Roche/Genentech; Seagen
Research Funding - Astellas Pharma (Inst); AstraZeneca Spain (Inst); Janssen Oncology (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - AstraZeneca Spain; Ipsen; Roche/Genentech
 
Begona Mellado
Consulting or Advisory Role - Amgen (I); Astellas Pharma; AstraZeneca; Bayer; Janssen; Pfizer; Pfizer (I); Roche; Roche (I)
Research Funding - Bayer; Janssen; Roche
Travel, Accommodations, Expenses - Janssen-Cilag; Roche (I)
 
Miguel Angel A. Climent Duran
Honoraria - Astellas Pharma; Bayer; Bristol-Myers Squibb; EUSA Pharma; Ipsen; Janssen; Merck; Novartis; Pfizer; Pierre Fabre; Roche; Sanofi
Consulting or Advisory Role - Astellas Pharma; Bayer; Bayer; Bristol-Myers Squibb; Celgene; Eisai; EUSA Pharma; Janssen Oncology; Janssen-Cilag; Merck; MSD Oncology; Pfizer; Roche/Genentech; Sanofi
Travel, Accommodations, Expenses - Ipsen; Janssen; Merck; Pfizer; Roche
 
Xavier Garcia del Muro
Consulting or Advisory Role - Bristol-Myers Squibb; EUSA Pharma; GlaxoSmithKline; Ipsen; Lilly; Pfizer; PharmaMar; Roche
Speakers' Bureau - Astellas Pharma; Bristol-Myers Squibb; Eisai; Pfizer
Research Funding - AstraZeneca
Travel, Accommodations, Expenses - Pfizer; Roche
 
Nuria Sala González
No Relationships to Disclose
 
Teresa Alonso Gordoa
Consulting or Advisory Role - Advanced Accelerator Applications/Novartis; Astellas Pharma; Bayer; Bristol-Myers Squibb; Eisai; Ipsen; Janssen-Cilag; Merck; Pfizer; Roche; Sanofi
Research Funding - Ipsen; Pfizer; Roche
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Ipsen; Pfizer; Sanofi
 
Elena Sevillano
Honoraria - Bristol-Myers Squibb; Janssen; MSD; Roche
Consulting or Advisory Role - Roche
Speakers' Bureau - Bristol-Myers Squibb; Janssen; MSD; Roche
Research Funding - Roche
Travel, Accommodations, Expenses - Pfizer; Roche
 
Montserrat Domenech
Consulting or Advisory Role - Sanofi
Speakers' Bureau - Bristol-Myers Squibb; Pfizer
Travel, Accommodations, Expenses - Lilly; Sanofi
 
Jesus Paramio
Research Funding - GlaxoSmithKline; Pfizer; Tesaro
Patents, Royalties, Other Intellectual Property - Diagnostic tools; EPigenetic drugs
 
Francisco X. Real
Research Funding - Janssen; VCN Biosciences
 
Nuria Malats
No Relationships to Disclose
 
Juan Luis Sanz
No Relationships to Disclose
 
Albert Font
Consulting or Advisory Role - Astellas Pharma; Janssen; Sanofi